Loading...
•
Jun 30, 2024
Xenon Pharmaceuticals Q2 2024 Earnings Report
Reported financial results for the second quarter ended June 30, 2024.
Key Takeaways
Xenon Pharmaceuticals reported a net loss of $57.9 million for the quarter ended June 30, 2024, compared to a net loss of $47.5 million for the same period in 2023. The company's cash and cash equivalents and marketable securities were $850.6 million as of June 30, 2024.
Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025.
MDD program on track with Phase 3 study expected to initiate in H2 2024.
Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in 2025.
Cash and cash equivalents and marketable securities were $850.6 million as of June 30, 2024.
Xenon Pharmaceuticals
Xenon Pharmaceuticals
Forward Guidance
Xenon anticipates having sufficient cash to fund operations into 2027.